Rivaroxaban superior to heparin in preventing blood clots after common orthopedic surgeries

March 30, 2020

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

The new data revealed that rivaroxaban cut the risk of major VTE by 75% without increasing the risk of bleeding, a common concern in patients taking a blood thinner. This international, double-blind, randomized controlled trial is the first to compare rivaroxaban against enoxaparin, a low molecular weight heparin, for clot prevention in people recovering from non-major orthopedic surgeries who often must restrict movements of the affected limb for a period of time to promote healing. However, even a brief period of reduced mobility can heighten a person's risk of developing dangerous blood clots that can lead to deep vein thrombosis (DVT), a condition where clots form in the veins of the legs, or pulmonary embolism, when clots travel and get lodged in the lungs.

"We must prevent VTEs in these patients because some can lead to pulmonary embolism, which can be fatal," said Nadia Rosencher, MD, senior consultant and anesthesiologist at Paris University, France, and one of the study authors. "This study represents a major step forward in our treatment of patients after many orthopedic procedures because it proves that we can more effectively prevent thrombosis with a once-daily oral medication versus a daily injection with the same safety."

Rosencher said taking injections of enoxaparin can be very cumbersome for patients, who sometimes require a nurse to help administer the medication. Additionally, this is a young population with a median age of 40 years, who often need to get back to work or caring for a family without added complications.

Rivaroxaban works by blocking the activity of the clotting protein factor Xa. It's known to be a strong anticoagulant, so researchers said they were somewhat surprised and reassured to find that bleeding risk was the same as with enoxaparin.

While most contemporary clinical guidelines recommend using anticoagulants to prevent blood clots after major orthopedic surgeries, including total knee and total hip replacements, that put patients at higher risk for VTEs, there is less agreement about prophylactic thrombosis treatment in patients at moderate risk for clots--for example, those undergoing ankle surgery, ligament repair or knee arthroscopy. Millions of people in the U.S. undergo these procedures each year and may need blood thinning to prevent clots from forming.

"In Europe, all the guidelines agree that some level of thromboprophylaxis should be given, but overall there is no agreement on what should be done for the patient population who remains at moderate risk for clots because of being immobilized during their recovery," Rosencher said. "In many ways these data are a win-win for patients--a pill with no jump in major bleeding events."

The study included 3,604 patients from 10 countries who were deemed to be at moderate VTE risk post-surgery by the investigator. Patients had to be immobilized for more than 15 days to be included. Patients were randomly assigned to receive rivaroxaban (10 mg once daily by mouth) or enoxaparin (40 ml once daily by subcutaneous injection). Because it was double-blinded, all patients received an injection and a tablet, so people in the rivaroxaban group took a daily pill but also got a placebo injection. Overall, patients had a median of 28 days of reduced mobility--1 in 3 were immobilized for one to two months, and 2 in 3 had to restrict activity for two weeks and up to one month.

The primary efficacy outcome of major VTE was the composite of symptomatic distal or proximal DVT, pulmonary embolism or VTE-related death during the treatment period and follow-up for one month, or asymptomatic proximal DVT at the end of treatment, which occurred in 4 out of 1,661 patients (0.24%) in the rivaroxaban group and 18 of 1,640 of patients (1.1%) in the enoxaparin group. Prespecified secondary outcomes were major and clinically relevant nonmajor bleeding, defined based on other studies, overt thrombocytopenia (low platelet count) and death from any cause. Bleeding rates did not differ between the rivaroxaban and enoxaparin groups (1.08% and 1.04%, respectively, for major plus nonmajor clinically relevant bleeding; 0.57% and 0.69%, respectively, for major bleeding). There were no deaths in either arm except one that occurred at the end of study follow-up and after a liver transplant.

"We saw a high number of patients in the low molecular weight heparin group with proximal asymptomatic DVT by compression ultrasounds, and these are quite dangerous as they can lead to pulmonary embolism that carries a high death toll," Rosencher said. "We expect to see expanded indications for rivaroxaban in other patients based on these data."

Rivaroxaban is currently approved by the U.S. Food and Drug Administration to prevent DVT that may lead to a pulmonary embolism after elective knee or hip replacement surgery; in some countries, it has a broader label to include use after lower-limb orthopedic surgery.
-end-
This study was simultaneously published online in the New England Journal of Medicine at the time of presentation. The trial was supported by Centre Hospitalier Universitaire de Saint-Etienne (France) and Bayer.

ACC.20/WCC will take place March 28-30, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC20/#WCCardio for the latest news from the meeting.

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.

American College of Cardiology

Related Pulmonary Embolism Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
In a systematic review of the worldwide published data on ''Venous thromboembolism (VTE) in COVID-19 patients'', researchers from the Department of Medicine I (MedUni Vienna), provide an in-depth analysis on the risk of VTE in patients hospitalised for COVID-19.

Trial clarifies which patients with acute pulmonary embolism can be managed at home
Patients with acute pulmonary embolism can be selected for home management using the sPESI score or the Hestia criteria, according to results of the HOME-PE trial presented in a Hot Line session today at ESC Congress 2020.1 Principal investigator Professor Pierre-Marie Roy of the University Hospital of Angers, France said: ''The pragmatic Hestia method was at least as safe as the sPESI score for triaging haemodynamically stable pulmonary embolism patients for outpatient care.''

Barriers exist to using risk stratification tools to evaluate pulmonary embolism in the ED
Common barriers exist to the use of risk stratification tools in the evaluation of pulmonary embolism in the emergency department and provide insight into where to focus efforts for future implementation endeavors.

Pulmonary embolism and COVID-19
Researchers at Henry Ford Health System in Detroit say early diagnosis of a life-threatening blood clot in the lungs led to swifter treatment intervention in COVID-19 patients.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

Better way to interpret blood tests to diagnose pulmonary embolism
A study led by Hamilton researchers has found a new way to interpret blood test results in patients who are investigated for blood clots in their lungs, a condition known as pulmonary embolism.

Reversed halo signs manifest in septic pulmonary embolism due to IV drug use
According to an article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology (AJR), reversed halo signs were frequently observed on the chest CT scans of patients with IV substance use disorder-related septic pulmonary embolism.

Treating pulmonary embolism: How safe and effective are new devices?
A new scientific statement from the American Heart Association identifies the risks and benefits of novel interventional devices compared to anticoagulation alone in the treatment of patients with pulmonary embolism.

Read More: Pulmonary Embolism News and Pulmonary Embolism Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.